The study, designed to assess the safety of 1207, will enroll 24 adult healthy male volunteers in Australia. In addition to safety data, the study will measure sensory perceptions of touch and warmth compared with placebo.
“Preclinical data suggest that 1207 could offer rapid and deep-penetrating relief as a topical treatment for neuropathic pain, or potentially for surgical incision pain prior to dermatological surgery,” said Daniel Gennevois, vice president of medical affairs at Anesiva. “With 1207 entering the clinic, we now have three novel products in various stages of advanced development.”
1207 is a new chemical entity with anesthetic properties that provide pain relief by binding to the fast sodium channel on neurons responsible for transmitting pain signals from nerve endings to the brain. Other potential applications for 1207 include pre-procedural use in dermatological surgery and post-surgical incision pain.